Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers

Published:2006-01 Issue:1 Volume:28 Page:55-72
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Bergman Arthur J.,Stevens Catherine,Zhou YanYan,Yi Bingming,Laethem Martine,De Smet Marina,Snyder Karen,Hilliard Deborah,Tanaka Wesley,Zeng Wei,Tanen Michael,Wang Amy Q.,Chen Li,Winchell Gregory,Davies Michael J.,Ramael Steven,Wagner John A.,Herman Gary A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference38 articles.

1. Gut peptides and type 2 diabetes mellitus treatment;Ahren;Curr Diab Rep,2003

2. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes;Drucker;Expert Opin Investig Drugs,2003

3. Therapeutic strategies based on glucagon-like peptide 1;Deacon;Diabetes,2004

4. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes;Drucker;Curr Pharm Des,2001

5. What do we know about the secretion and degradation of incretin hormones?;Deacon;Regul Pept,2005

Cited by 251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants;Journal of Medicinal Chemistry;2023-08-30

2. Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers;Clinical and Translational Science;2023-06-21

3. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome;Biomedicine & Pharmacotherapy;2023-05

4. Pharmacokinetics and relative bioavailability of sitagliptin hydrochloride and sitagliptin phosphate tablets formulations: a randomized, open-label, crossover study in healthy male volunteers;Generics and Biosimilars Initiative Journal;2023-04-15

5. Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products;Diabetes Therapy;2022-12-16